Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present GW Pharmaceuticals Plc. (NASDAQ: GWPH).

Full DD Report for GWPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: GWPH)

NYC sees marijuana revenue stream
New York state would gain $435.7M annually in tax revenue for legalized weed, while New York City would get about $336M, according to NYC Comptroller Scott Stringer. More news on: Aurora Cannabis Inc., Aero Grow International, Inc., American Cannabis Company, Inc., Read more ......
Source: SeekingAlpha
Date: May, 17 2018 04:56
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Epidiolex® (cannabidiol oral solution) in Lennox-Gastaut Syndrome
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy – – Both doses significantly reduced dr...
Source: GlobeNewswire
Date: May, 16 2018 17:00
Cannabis Is Fueling The Next Era of Medical Revolution
Palm Beach FL – May 16, 2018 – Talk of legalizing marijuana throughout North America has been growing like a weed. Up to 88% of Americans favor its medicinal use, thanks to a growing body of research supporting marijuana’s use for medical purposes.  Some studies even su...
Source: MarketNewsUpdates.com
Date: May, 16 2018 08:02
Marijuana Stock Report: Because, Of Course, Mitch McConnell Is Against Legal Weed
The North American Marijuana Index retreated on Tuesday, as pot stocks lost ground following Monday’s brief respite from the downward spiral. Not unexpectedly, Senate Majority Leader Mitch McConnell (R-Kentucky) announced his continued support for cannabis prohibition , dashing the h...
Source: Pot News
Date: May, 09 2018 04:40
GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q2 2018 Results - Earnings Call Transcript
GW Pharmaceuticals plc (GWPH) Q2 2018 Earnings Conference Call May 08, 2018 04:30 PM ET Executives Stephen Schultz - Vice President, Investor Relations Justin Gover - Chief Executive Officer Scott Giacobello - Chief Financial Officer Volker Knappertz - Chief Medical Officer J...
Source: SeekingAlpha
Date: May, 08 2018 20:26
GW Pharmaceuticals misses by $0.64, beats on revenue
GW Pharmaceuticals (NASDAQ: GWPH ): Q2 EPS of -$3.12 misses by $0.64 . More news on: GW Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:09
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2018 Financial Results and Operational Progress
- Positive unanimous vote at Epidiolex ® (cannabidiol) FDA Advisory Committee meeting - - NDA PDUFA goal date scheduled for June 27, 2018 - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NA...
Source: GlobeNewswire
Date: May, 08 2018 16:00
GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2018 Health Care Conference
LONDON and CARLSBAD, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announc...
Source: GlobeNewswire
Date: May, 08 2018 13:00
Notable earnings after Tuesday's close
AAOI , AAXN , AGTC , ALEX , AMBC , APEI , ARNA , AVD , BECN , BIO , BOJA , BW , CA , CERS , CHUY , CISN , CLVS , CORT , CSOD , CTRE , CUTR , CVG , DEI , DIOD , DIS , DVAX , DXPE , EA , ECPG , EPR , ESE , ESIO , ETSY , EVC , EXTR , FANG , FARM , FOSL , ...
Source: SeekingAlpha
Date: May, 07 2018 17:35
Will Government End Gridlock And Entice Cannabis Investors?
Jeff Sessions doesn’t scare everyone in the cannabis sector. Even though Sessions was quoted saying , "I reject the idea that America will be a better place if marijuana is sold in every corner store," many say that Sessions could impose much harsher penalties if his goal is truly tryi...
Source: Pot News
Date: May, 06 2018 20:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17151.01150.27151.822148.80475,982
2017-11-10111.08112.17112.55110.50214,917
2017-11-09111.19111.82112.9045109.60248,881
2017-11-08113.19111.44114.19110.625237,810
2017-11-07113.54113.31114.00112.34219,579

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1857,144159,67935.7868Short
2018-05-1752,066292,18717.8194Cover
2018-05-1689,863391,31022.9647Cover
2018-05-1550,107128,51938.9880Short
2018-05-1435,775120,37729.7191Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GWPH.


About GW Pharmaceuticals Plc. (NASDAQ: GWPH)

Logo for GW Pharmaceuticals Plc. (NASDAQ: GWPH)

GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group s lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex R Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications. GW has assembled a large in house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant based prescription pharmaceutical products. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.

 

Contact Information

 

 

Current Management

  • David Kirk / Finance Director
  • Geoffrey Guy / Executive Chairman

Current Share Structure

     


    Recent Filings from (NASDAQ: GWPH)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 08 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 19 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 19 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 06 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 03 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 06 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 23 2018

     

     


    Daily Technical Chart for (NASDAQ: GWPH)

    Daily Technical Chart for (NASDAQ: GWPH)


    Stay tuned for daily updates and more on (NASDAQ: GWPH)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: GWPH)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    The Subway Trader
    @TheSubwayTrader

     

     


    Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GWPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of GWPH and does not buy, sell, or trade any shares of GWPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/